TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) ("Cybin†or the "Company†), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has launched an at-the-market equity program (the "ATM Program†) to allow Cybin to issue and sell up to US$100,000,000 of common shares in the capital of the Company (the "Shares†) from treasury to the pu. ...